SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Arqit Quantum, Inc. engages in the provision of cybersecurity services via satellite and terrestrial forms. Its product is QuantumCloud which secures devices with cloud-based quantum encryption. The company was founded by David John Williams and David James Bestwick on April 26, 2021 and is headquartered in London, the United Kingdom.

Arqit Quantum Inc

Arqit Quantum is experiencing high volatility as investors track significant insider accumulation and a tightening share float, with the community actively speculating on potential government contract catalysts and a possible short squeeze. Sentiment is largely divided between bullish investors eyeing the stock's role in the quantum security sector and skeptics concerned about the company's limited revenue and ongoing legal overhangs.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense downward pressure and widespread community skepticism as investors debate the sustainability of its debt-fueled Bitcoin accumulation strategy and the potential for systemic risk. The stock is a focal point for intense conflict between those calling for a structural collapse and those viewing the current volatility as a generational buying opportunity.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is rallying as investors react to strong quarterly growth, a transformative shift toward a semiconductor-based business model, and a high-profile partnership with Midjourney. While the community is debating potential future share offerings and the long-term competitive landscape, bullish sentiment remains centered on the company's proprietary chip technology and aggressive expansion into point-of-care AI imaging.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently trending due to its pivotal role as a primary power infrastructure provider for AI data centers, with community sentiment fueled by major contract wins and ongoing hyperscaler demand. While the stock has seen explosive long-term growth, investors are actively debating its current valuation levels and the volatility associated with its rapid ascent in the energy space.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is surging as investors pivot to its new AI infrastructure identity, fueled by the formal completion of its Northern Data acquisition and the launch of the 'Quake AI' division. The community is buzzing over the massive influx of GPU capacity and potential cloud contracts, creating high conviction among bulls regarding a massive short squeeze and long-term valuation re-rate.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is surging as the memory sector benefits from critical supply constraints and strong AI data center demand, with market participants eagerly awaiting upcoming earnings reports for key sector leaders. The stock's parabolic climb has ignited intense community debate, with many investors highlighting massive long-term gains while skeptics warn of a potential bubble and increased volatility ahead of significant economic events.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are trending as investors weigh an upcoming FDA advisory committee meeting for its mRNA flu vaccine against the company's broader efforts to expand its pipeline in oncology and rare diseases. The community remains sharply divided, with bulls pointing to long-term pipeline potential and clinical progress, while bears continue to scrutinize the company's path to profitability and recent regulatory hurdles.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is gaining significant momentum as investors digest recent positive clinical milestones and anticipate the upcoming start of the Phase 3 lung cancer trial, which serves as a key validator for the company's manufacturing progress. Community discussions are heavily focused on the potential for a large-scale M&A event or partnership, with many interpreting the current accumulation by institutional holders as a sign of high-conviction value ahead of the company's late-stage pipeline milestones.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors react to a newly announced multi-year joint research agreement with Honda, which validates the company's solid-state battery technology through rigorous benchmarking. The community is actively debating the significance of this OEM partnership, weighing the technical validation against the long-term timeline for commercial production.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is seeing a strong rally driven by institutional interest and optimism surrounding the upcoming FDA review of compounded weight-loss peptides. While the community is actively debating the stock's path toward previous highs and the potential for a short squeeze, many are focused on the company's expanding telehealth platform and its ability to capture market share in the growing GLP-1 and wellness space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS Monday will be the 44th Day since the78th Event. 
72nd Dec 26th - 78th May 11 --- / 6 Events in 136 Days / Approximately 1 Event Every 22 Days... 
Monday is the Bullseye to see the 80th Event PR  
 
- and for this Board Full of INCH THICK IDIOT Tools, the reason the Share Price Launched on each of the Previous Event PR&#39;s, is the Same Reason, it will Just about double to $18/ $20 on the 80th ... That is - SMART MONEY ... Much Smarter than US ( $ABBV / $RHHBY $BMY) Knows BAT does not offer effective Remission Maintenance - they Know its Gps Doing what its done in all 7 Prior Trials --- Prevent Relapse and Extend Survival - that is Directly Correlated with Immune Response- The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA From the INTERIM ANALYSIS at 60 Events... You penny flipping idiots are going regret for the rest of your Miserable Short Lives, for selling for anything less than $80 Per Share --- now you know.

Easy E

5,500% ROI this quarter

veecee

Bill Day

$SLS 39 Days 
Institutional Funds Live for these massive near term catalysts - GPs Phase 3 Results are Coming, they Are Inevitable and worth every Nickel of $40B to Big Pharma.   
   
Gps Immunotherapy is getting the Fda Approval to Treat 100,000 AML patients currently in Remission.   
The xCCo Estimated $280K Revenue Per Patient Year 1.   
Indefinite Multi Year Dosing Regime Compounds the Rev.   
- $28B Total Addressable Market    
- Right out of the GATE   
Plus 12,500 AML CR2/3 Patients who are Eligible Each Year ... Just this CR2/3 Market is worth $67 per Share.   
   
TAM - rNPV - Just for CR2/3

StockTwits Web

SELLAS Life Sciences Group Inc

Abbvie Inc

Roche Holdings AG ADR

Bristol-Myers Squibb Co.

 Monday will be the 44th Day since the78th Event. 
72nd Dec 26th - 78th May 11 --- / 6 Events in 136 Days / Approximately 1 Event Every 22 Days... 
Monday is the Bullseye to see the 80th Event PR  
 
- and for this Board Full of INCH THICK IDIOT Tools, the reason the Share Price Launched on each of the Previous Event PR's, is the Same Reason, it will Just about double to $18/ $20 on the 80th ... That is - SMART MONEY ... Much Smarter than US ( 

) Knows BAT does not offer effective Remission Maintenance - they Know its Gps Doing what its done in all 7 Prior Trials --- Prevent Relapse and Extend Survival - that is Directly Correlated with Immune Response- The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA From the INTERIM ANALYSIS at 60 Events... You penny flipping idiots are going regret for the rest of your Miserable Short Lives, for selling for anything less than $80 Per Share --- now you know.